A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial

Blumenschein, G. R.; Paulus, Rebecca; Robert, Francisco; Fossella, Frank V.; Werner‐Wasik, Maria; Doescher, P.; Choy, Hak; Komaki, R.

doi:10.1200/jco.2008.26.15_suppl.7516

Cited by 23 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Objective responses were achieved by 54 patients (62%), including 24 patients (28%) with complete responses. Median OS was 22.7 months and 2-year OS was 49.3% [60]. These encouraging results are superior to survival data reported in other RTOG studies of locally advanced NSCLC.…”

Section: Cetuximab Plus Radiation Therapysupporting

confidence: 53%

“…In the phase 2 RTOG 0324 study, 93 patients with unresectable stage III NSCLC were treated with cetuximab 400 mg/m 2 on day 1 of week 1 and then 250 mg/m 2 weekly until completion of therapy [60]. During weeks2 to 8, radiation at a dose of 63 Gy was delivered in 1.8-Gy daily fractions in combination with weekly paclitaxel 45 mg/m 2 and carboplatin AUC 2.…”

Section: Cetuximab Plus Radiation Therapymentioning

confidence: 99%

See 1 more Smart Citation

Cetuximab in combination therapy: from bench to clinic

Gerber

Choy

2010

Cancer Metastasis Rev

View full text Add to dashboard Cite

Cetuximab, a chimeric IgG(1) monoclonal antibody directed against the ligand-binding domain of the epidermal growth factor receptor, offers a paradigm for the combination of molecularly targeted therapies with cytotoxic agents. In preclinical models, the addition of cetuximab to chemotherapy or radiation therapy enhances antitumor activity. Proposed mechanisms include reducing tumor cell proliferation, angiogenesis, and DNA repair capacity; increasing apoptosis; and inducing cell cycle arrest at treatment-sensitive points. These effects may enhance and restore tumor sensitivity to cytotoxic therapies. In clinical trials, the addition of cetuximab to chemotherapy improves outcomes of patients who had previously failed such agents, as illustrated in irinotecan-resistant and oxaliplatin-refractory metastatic colorectal cancer. As initial therapy, the addition of cetuximab to chemotherapy extends survival in colorectal cancer, lung cancer, and head and neck cancer. Combining cetuximab with radiation therapy extends survival in locally advanced head and neck cancer. As predictive biomarkers are identified, it may become possible to select patients most likely to benefit from such combinations.

show abstract

Section: Cetuximab Plus Radiation Therapysupporting

confidence: 53%

Section: Cetuximab Plus Radiation Therapymentioning

confidence: 99%

Cetuximab in combination therapy: from bench to clinic

Gerber

Choy

2010

Cancer Metastasis Rev

View full text Add to dashboard Cite

show abstract

“…Adverse events related to treatment included grade 4 hematologic toxicities in 17 (20%) patients, grade 3 esophagitis in seven (8%) patients, and grade 3-4 pneumonitis in six (7%) patients. There were five grade 5 events [31]. A phase II randomized trial en-rolled 106 patients with unresectable stage III NSCLC treated with thoracic radiation and carboplatin plus pemetrexed on day 1, every 3 weeks for four cycles, with or without cetuximab at the standard dose for 7 weeks.…”

Section: Earlier Stagesmentioning

confidence: 99%

Cetuximab and Other Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer

et al. 2009

View full text Add to dashboard Cite

show abstract

“…In addition, there are data for single agent cisplatin in combination with XRT: a single randomized trial demonstrated a survival advantage for the addition of low-dose daily cisplatin (6 mg/m 2 ) to split course radiation therapy vs. XRT alone; a third arm featuring weekly cisplatin (30 mg/m 2 ) yielded similar survival to the daily arm [46]. Cetuximab concurrent with radiation therapy has demonstrated efficacy in the treatment of head and neck cancer [46] and has been studied in several phase II studies in NSCLC [47,48]. For example, in a recent phase II study in patients with LA-NSCLC (median age of 64), patients underwent treatment with weekly carboplatin, paclitaxel and cetuximab concurrent with radiation followed by two cycles of consolidation carboplatin, paclitaxel and cetuximab.…”

Section: Stage IIImentioning

confidence: 98%

NSCLC in the Elderly—The Legacy of Therapeutic Neglect

Weiss

Langer

2009

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Although the majority of patients diagnosed with non-small cell lung cancer (NSCLC) are elderly, most clinical trials available to guide care either exclude the elderly or underrepresent them. This disregard for the elderly lung cancer patient extends to the clinical realm, where the elderly with lung cancer are less likely to be treated with either curative, or life-extending, palliative therapy. Few elderly-specific phase III trials are available to provide level I evidence. However, subgroup analyses and meta-analyses of large clinical trials enrolling substantial numbers of elderly patients are available to guide care, although these are potentially subject to selection bias. These trials suggest that the fit elderly derive as much benefit from surgery, chemoradiation, and platinum-based doublet chemotherapy as younger patients across all stages of disease. For the less fit elderly, in particular those with limited performance status or significant co-morbidities, less aggressive regimens are likely preferred, with the goal of extending life and delaying or suppressing cancer symptoms. Ultimately, care decisions must incorporate knowledge of the literature, evaluation of the patient's clinical characteristics, and patient priorities. The elderly should be aggressively recruited to clinical trials, including elderly-specific trials and trials of patients with limited performance status and co-morbidities.

show abstract

A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial

Cited by 23 publications

References 0 publications

Cetuximab in combination therapy: from bench to clinic

Cetuximab in combination therapy: from bench to clinic

Cetuximab and Other Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer

NSCLC in the Elderly—The Legacy of Therapeutic Neglect

Contact Info

Product

Resources

About